No profile data available.
Grifols, S.a. (GRFS) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Barcelona, Spain, with about 25,258 full-time employees.
It reported revenue of 7.52 billion EUR for fiscal year 2025, up 4.3% from fiscal year 2024, and net income of 402.00 million EUR. In Q2 2026 (the quarter ended June 30, 2026) revenue was 1.87 billion EUR, down 0.9% from a year before. Its largest business segment, Biopharma, brought in 86% of segment revenue in fiscal year 2025; USA and Canada was the largest region with 57%. Its market capitalization was $5.08 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Grifols reported 7.52 billion EUR in revenue for fiscal year 2025, up 4.3% from 7.21 billion EUR in fiscal year 2024. In Q2 2026 revenue was 1.87 billion EUR.
Biopharma, with 6.49 billion EUR or 86% of segment revenue in fiscal year 2025. Next: Diagnostic (9%) and Others (3%).
USA and Canada: 57% of revenue by region in fiscal year 2025, followed by Rest of World (22%).
$5.08 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Amneal Pharmaceuticals, Inc. (AMRX), Ligand Pharmaceuticals Incorporated (LGND), Crispr Therapeutics AG (CRSP), Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. (GEDSF).